Phio Pharmaceuticals (NASDAQ:PHIO) & Kazia Therapeutics (NASDAQ:KZIA) Head-To-Head Review

Phio Pharmaceuticals (NASDAQ:PHIO) and Kazia Therapeutics (NASDAQ:KZIA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.

Institutional and Insider Ownership

3.6% of Phio Pharmaceuticals shares are held by institutional investors. Comparatively, 4.1% of Kazia Therapeutics shares are held by institutional investors. 2.1% of Phio Pharmaceuticals shares are held by company insiders. Comparatively, 1.0% of Kazia Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Phio Pharmaceuticals and Kazia Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Phio Pharmaceuticals N/A -74.97% -62.32%
Kazia Therapeutics N/A N/A N/A

Risk and Volatility

Phio Pharmaceuticals has a beta of 1.51, indicating that its stock price is 51% more volatile than the S&P 500. Comparatively, Kazia Therapeutics has a beta of 1.84, indicating that its stock price is 84% more volatile than the S&P 500.

Earnings & Valuation

This table compares Phio Pharmaceuticals and Kazia Therapeutics’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Phio Pharmaceuticals $140,000.00 36.91 -$7.36 million ($1.04) -0.14
Kazia Therapeutics $1.12 million 23.39 -$7.34 million ($1.25) -3.37

Kazia Therapeutics has higher revenue and earnings than Phio Pharmaceuticals. Kazia Therapeutics is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations for Phio Pharmaceuticals and Kazia Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Phio Pharmaceuticals 0 0 0 0 N/A
Kazia Therapeutics 0 0 0 0 N/A

Summary

Kazia Therapeutics beats Phio Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

Phio Pharmaceuticals Company Profile

Phio Pharmaceuticals Corp., a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company's lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye. The company also develops Samcyprone, a topical formulation of the small molecule diphenylcyclopropenone that is in a Phase IIa clinical trial for the clearance of common warts; RXI-231, an sd-rxRNA compound targeting tyrosinase, as a cosmetic ingredient that may enhance the appearance of uneven skin tone and pigmentation; and RXI-185, an sd-rxRNA compound targeting collagenase, as a cosmetic ingredient that may improve the appearance of wrinkles or skin laxity. In addition, it develops RXI-109, a Phase I/II clinical trial that reduces the progression of retinal scarring. The company has collaborations with the Center for Cancer Immune Therapy; Gustave Roussy; Medigene AG; PCI Biotech; and Karolinska Institutet. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. The company was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

Kazia Therapeutics Company Profile

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops therapies for a range of oncology indications. Its lead product is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway that is in Phase II clinical trials to treat glioblastoma multiforme. The company is also developing TRX-E-002-1 (Cantrixil), a third-generation benzopyran molecule, which is in Phase I clinical trials to treat ovarian cancer. It has collaboration agreements with The University of York, The Children's Cancer Institute Australia, The Mater Institute in Queensland, the University of Boston, and St Jude Children's Research Hospital, as well as Dana-Farber Cancer Institute. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.

Receive News & Ratings for Phio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.